1. Introduction
Multiple sclerosis (MS) is an inflammatory and demyelinating disease affecting the central nervous system (CNS). Its etiology is still unknown, although it is thought to be the result of immune dysregulation induced by both genetic and environmental factors [1]. The pathogenesis of this condition is mainly autoimmune, with the participation of both innate and acquired immunity. The immune response to CNS antigens is mediated by activated autoreactive CD4+ T cells, with contributions from other cells and immune system cytokines [2]. Of the various environmental factors related to the disease, vitamin D (VD) is thought to play a major role in development and progression owing to its role in immune regulation [3,4].
In studies of MS and in the murine animal model of experimental autoimmune encephalomyelitis (EAE), the presence of VD has been correlated with increased expression of anti-inflammatory cytokines (IL-4; IL-10) and transforming growth factor β (TGF-β), a decrease in the expression of certain pro-inflammatory cytokines such as IL-12, IL-17, and IFN-γ [5], and modulation of the T cell response [6], thus highlighting its immunoregulatory role. VD performs its functions by interacting with its receptor (VDR), which is expressed extensively on cells of the immune system. After VD activates the VDR, it binds to specific DNA regions, leading to promotion or suppression of gene transcription [7].
TGF-β is a superfamily of cytokines and growth factors involved in the processes of cell growth and differentiation in the immune system [8]. TGF-β signaling has important anti-inflammatory effects, such as inhibiting cell proliferation mediated by IL-2 and IL-12, decreasing the production of tumor necrosis factor (TNF) and lymphotoxins, and intervening in the maintenance of FOXP3+ regulatory T cells. However, in the presence of IL-6, it promotes differentiation toward Th17, a cell phenotype that plays an important role in the immunopathogenesis of EAE and MS [9,10,11].
Activation and phosphorylation of the TGF-β type II receptor (TGF-βRII) triggers R-SMAD proteins (SMAD2/3). These form a complex with the mediator Co-SMAD4, which translocates to the nucleus to regulate transcription of specific genes. Two inhibitory I-SMAD proteins (SMAD6 and SMAD7) run a negative feedback loop on TGF-β signaling, by competing with R-SMADs for receptor binding, thus inhibiting their phosphorylation [10,11]. Apart from the SMAD pathway, TGF-β signaling is carried out by other non–SMAD-dependent pathways (e.g., Ras-ERK, mitogen-activated protein kinase [MAPK], c-Jun N-terminal kinase [JNK], TAK-MKK3/6-p38) [12,13] and is modulated at several levels by regulatory proteins, such as activated STAT inhibitor proteins (PIAS), which are able to suppress SMAD3 transcriptional activity [14,15]. VD has been associated with the immunoregulatory functions of TGF-β. It has demonstrated the ability to increase transcription factors that bind to the TGF-β promoter, activate alternative pathways mediated by mitogen-activated protein kinase (MAPK), and modify the half-life of TGF-β mRNA, thus suggesting a post-transcriptional mechanism. The precise direct or indirect mechanisms by which VD interacts with TGF-β are still unclear [16].
The TGF-β superfamily also includes bone morphogenetic proteins (BMPs), which are a group of growth factors whose functioning also depends on signaling pathways common to TGF-β via SMAD- and non–SMAD-dependent pathways [17,18]. They have been linked to cell maintenance and differentiation processes in various tissues. In the CNS, they act primarily as promoters of astrocyte differentiation and suppressors of oligodendroglial differentiation [19]. They also play an important role in the immune system in T-cell differentiation and regulation of cellular and humoral responses [17,20]. BMP signaling has been shown to be altered in EAE and MS by promoting a pro-inflammatory response in the disease [21,22].
In this study, we aimed to analyze the regulatory effect of VD on TGF-β signaling pathway gene expression in vivo in patients with relapsing-remitting MS (RRMS).
2. Results
2.1. Patient Characteristics
A total of 21 patients were included in the study. The median age of patients was 39 (IQR, 20–56) years, and most were women (76.2%). Natalizumab was the most common treatment (Table 1). Serum VD levels increased from baseline to six months.
2.2. Gene Expression of TGF-β Related Genes and Relationship with VD Supplementation
Analysis of TGF-β related gene expression revealed that the mean expression of the SMAD7 gene increased 3.66-fold (p value = 0.033) from baseline to six months of treatment, and 5.32-fold (p value = 0.008) from the first to the sixth month of treatment. The mean expression of SMAD7 in the first month was lower than at baseline, although the difference was not significant. Increased mean expression of ERK1 was also observed at six months compared to one month of supplementation (1.84-fold; p value = 0.002). No significant differences were found in the mean expression of ZMIZ1, BMP2, BMPRII, BMP4, or BMP5 at the study timepoints (Figure 1), although a trend toward overexpression of BMP5 was observed at one month and six months of VD supplementation compared to baseline. No correlation was found between expression variables of the different study genes and serum VD levels. Individual expression data and variables used for comparison in all figures are provided in the Supplementary Material.
2.3. Gene Expression of TGF-β Related Genes under Natalizumab Treatment and VD Supplementation
As natalizumab was the main treatment, mean changes in TGF-β related gene expression were analyzed, specifically in this group of patients. The comparison revealed that only BMPRII was differentially expressed after one month of VD supplementation. Thus, BMPRII was overexpressed 3.66-fold in the non–natalizumab- versus natalizumab-treated group (p value = 0.001) (Table 1, Figure 2). In addition, a trend toward overexpression of BMPRII was observed in non–natalizumab-treated patients versus natalizumab-treated patients during follow-up (baseline, one month, and six months). However, it was only after one month that this difference became statistically significant.
In contrast, there was a trend toward decreased mean expression of BMP5 from baseline to six months in natalizumab-treated patients, while in non–natalizumab-treated patients, the trend was toward increased mean expression. Nevertheless, these changes were not statistically significant.
2.4. Gene Expression of TGF-β Related Genes and Clinical-Radiological Disease Activity
The expression of genes related to inflammation could be associated with the clinical and radiological characteristics of affected patients. Therefore, we compared the group of patients whose Rio-Score improved or remained unchanged at one year of the study with those whose Rio-Score worsened and found a significant difference in the mean expression of ERK1 at baseline (2.25-fold higher expression in the improvement or no change in Rio-Score group; p value = 0.045). Significant differences were also found in mean BMP2 expression at baseline (7.44-fold higher expression in the worsening Rio-Score group; p value = 0.008) and after six months of supplementation (3.92-fold increased expression in the Rio-Score worsening group; p value = 0.023), and in mean BMP5 expression at one month of supplementation (23-fold increased expression was observed in the worsening Rio-Score group; p value = 0.004) (Table 1, Figure 3). A trend toward increased expression of BMPRII after six months of supplementation was observed in the worsening group, and a trend toward increased expression of SMAD7 was observed in both groups after six months of supplementation. However, these changes were not statistically significant.
A total of four patients experienced a relapse during the study. Comparison between patients who experienced a relapse and those who did not showed a significant difference in mean BMP2 expression at baseline in the relapse group (5.94-fold; p value = 0.017) (Figure 4). A trend was also observed toward increased expression of BMP5 at one month and BMPRII at one and six months in the group of patients who experienced a relapse. However, these changes were not statistically significant.
Comparison between the patients whose EDSS improved at one year of the study and those whose disease worsened or remained unchanged showed a significant difference in BMP5 mean expression at baseline (15.55-fold higher in the EDSS improvement group; p value = 0.019) (Table 1, Figure 5). In contrast, the trend in expression seems to have been lower at one and six months in the EDSS improvement group (data not statistically significant).
A non–statistically significant trend toward overexpression of BMPRII was also observed in the worsening or no-change EDSS group during follow-up (baseline, one month, and six months).
3. Discussion
VD is an environmental factor that is intimately related to the development of MS [23]. It plays an immunoregulatory role by activating various pathways. One of these is the TGF-β pathway, which, through its different cytokines and growth factors, promotes mainly anti-inflammatory functions, such as the generation and maintenance of regulatory T cells or the inhibition of pro-inflammatory cytokines [24,25]. However, TGF-β is also able to promote differentiation toward Th17, a cell phenotype involved in the pathogenesis of MS and EAE [26,27]. To carry out these functions, TGF-β uses different signaling pathways. These may depend or not on SMAD proteins [28,29,30], which in turn are regulated at different levels by various regulatory proteins. Therefore, knowledge of the changes caused by VD supplementation in the expression of genes involved in this pathway is essential if we are to understand the molecular effects of this treatment and to establish future biomarkers of response to it.
In this study, CD4+ T cells extracted from peripheral blood of RRMS patients, both before and after VD supplementation according to standard clinical practice, were examined for changes in the expression of TGF-β–related genes.
We found significant changes in SMAD7 expression at six months from baseline and at one month from the start of supplementation. We also found significant differences in ERK1 expression at six months compared to the first month after initiation of supplementation. SMAD7 exerts a negative feedback effect on the SMAD pathway of TGF-β [31,32], whereas ERK1 is part of the non-SMAD pathway [8,9,11]. These findings suggest that TGF-β is likely to carry out its functions primarily through the non-SMAD pathway, while the canonical SMAD pathway is inhibited due to overexpression of SMAD7 under the influence of VD. An EAE study in mice revealed that when T cells lacked TGF-βRII, they did not differentiate to Th17, but when they were treated with a TGF-βRI kinase inhibitor (SB-431542) or overexpressed Smad7, the Th17 population was maintained through activation of non–SMAD-dependent genes [13]. We did not find an association between VD levels and the expression of these genes, thus suggesting that VD would be regulating them not directly, but in a more complex way, probably by acting on other, different pathways that indirectly end up favoring overexpression of SMAD7 and ERK1. In this sense, other studies have demonstrated that VD can activate alternative non-SMAD pathways of TGF-β by activating transcription factors that bind to the TGF-β promoter or even influencing its post-transcriptional regulation [16]. However, in another study, again in mice, the authors found that the active form of VD (1,25(OH)2D3) promoted Smad3 expression and inhibited Smad7 expression during differentiation to Th17 [33]. In humans with MS supplemented with VD, one study found significant differences in expression in genes related to the Th17 population [34]. Another study, also in humans with MS who received VD, found increased expression of IL-10 but not TGF-β1 in treated patients [35]. The influence of VD on gene expression may change depending on the cell type of the immune system, as shown in another work in MS patients [36]. Despite the difference in study models, the mechanism by which VD regulates TGF-β is still unclear.
Th17 facilitates disruption of the blood–brain barrier, thus enabling the transit of inflammatory cells into the CNS [26]. IL-17A and other Th17-responsive cytokines have been detected in CNS lesions in both MS and EAE [37], although it is difficult to access the CNS compartment in MS [10]. Therefore, we investigated whether the mechanism of action of disease-modifying treatment (DMT) would influence TGF-β gene expression. In our study, all patients were receiving DMT, nine of them with natalizumab. Natalizumab is a monoclonal antibody directed against the α-chain of the VLA-4 integrin and is a very potent inhibitor of cell migration into tissues, including the CNS. It reduces relapses and active lesions very effectively in the MRI of RRMS patients [38,39]. Of all of the genes studied, significant differences in BMPRII expression were only found one month after initiation of supplementation in those patients who were not receiving natalizumab. A trend toward overexpression of BMPRII was observed in non–natalizumab-treated patients compared to natalizumab-treated patients, both at baseline and after six months. With respect to BMP5, we observed a decreasing trend in mean expression from baseline to six months in natalizumab-treated patients versus an increasing trend in non–natalizumab-treated patients. However, these changes were not statistically significant. The fact that there is an effective blockade of cell entry into the CNS depending on treatment with natalizumab and, therefore, apparently different CNS compartments, does not seem to be a determinant in modifying TGF-β gene expression, except in BMPRII. Nonetheless, it cannot be excluded that the other mechanisms of action of DMT will affect gene expression of TGF-β in regard to VD. This finding would be in line with other works, such as a study in which the authors measured expression of BMP genes in MS lesions and found increased expression of BMP2, BMP4, BMP5, BMP7, BMPRII, and pSMAD1/5/8 in astrocytes, microglia/macrophages, and neurons [22]. In another study, in this case in EAE, overexpression of Bmp4, Bmp6, and Bmp7 was observed in the lumbar spinal cord of mice with active EAE [40].
The Rio-Score is an index created from a combination of relapse data, sustained EDSS changes, and MRI lesions that is used to assess the degree of therapeutic response to interferon-beta in RRMS patients [41,42,43]. In our case, we used the Rio-Score as a simple measure of the clinical-radiological characteristics of the disease to assess whether they would influence gene expression in the study. Significantly higher expression of ERK1 was found at baseline, normalizing at one month and six months after the initiation of supplementation in patients whose Rio-Score improved or remained unchanged at one year after the study. The higher expression of ERK1 at baseline would suggest activation of the non-SMAD pathway of TGF-β [12,13], which normalized as soon as patients reached sufficiently high serum values of VD after one month of supplementation. Thus, the anti-inflammatory effects of TGF-β are mediated through the SMAD protein–dependent pathway. In patients with a worsening Rio-Score at one year, expression of BMP2 was higher at baseline and six months, and that of BMP5 was increased at one month, indicating that BMP signaling is altered in MS patients [17], although its expression does not seem to be related to VD levels and did not change after serum levels returned to normal. Along the same lines, we also observed overexpression of baseline BMP2 in patients whose disease relapsed and overexpression of BMP5 in patients whose EDSS improved, indicating dysregulation of BMP signaling in MS patients. One study found increased BMP2 expression in the serum of untreated RRMS patients, and its levels correlated with those of BMP4 and BMP5 [44]. BMPs are multifunctional proteins involved in cell differentiation processes, such as astrogliogenesis, oligodendrogliogenesis, and neurogenesis [45,46,47,48]. BMP signaling also has effects on immune system differentiation, facilitating, together with TGF-β, the differentiation of FOXP3+ regulatory T cells [49]. In MS patients, this dysregulation of BMP signaling leads to proliferation of pro-inflammatory cell lines, thus promoting disease activity [21].
Given the lack of consensus on the dosage or the time of administration, VD supplementation was prescribed according to standard clinical practice criteria. In our study, there were no withdrawals from treatment or related adverse effects. This observation is in line with other published studies, which state that VD supplementation is safe and tolerable with immunological benefits in MS patients [6]. Data are currently available from two large clinical trials examining VD supplementation in MS (SOLAR and CHOLINE). While neither study met its primary endpoints (no evidence of disease activity [NEDA-3] at 48 weeks in SOLAR and annualized relapse rate at 96 weeks in CHOLINE), both showed effects on some secondary endpoints [50,51,52]. Although there are discrepancies between observational studies and clinical trials with VD, the evidence would still support the recommendation to prescribe supplementation in MS patients with insufficient VD levels [53,54].
Munger et al. studied changes in global gene expression in the blood cells of MS patients who received VD supplementation, suggesting that the activity of MS is affected by unbalanced VD-related gene expression [55]. The differences with our study are that, first, we focused on the changes in TGF-ß signaling, whereas Munger et al. provided a whole transcriptomic profile. Second, we measured expression in T lymphocytes, whereas Munger et al. used whole blood. And third, patients in the Munger study were treated with interferon ß-1b. However, our results also suggest that regulation of VD-expressed genes may affect the activity of MS.
A limitation of the study may be the lack of a healthy control group to measure gene expression changes after VD supplementation. The expression of SMAD7 increased by a factor of 3.6 in multiple sclerosis (MS) patients after six months of VD supplementation. Similarly, SMAD7 expression exhibited a 2.3-fold increase in healthy donors compared to MS patients [10]. While our study did not incorporate a healthy control group, our findings suggest a restoration of "normal" SMAD7 levels after six months of VD supplementation [10]. No comparisons are available for the remaining genes analyzed in this study.
4. Materials and Methods
4.1. Patients
Patients were recruited and samples taken at the Neurology Department of Hospital General Universitario Gregorio Marañón, Madrid, Spain between 2016–2017. The inclusion criterion was a diagnosis of RRMS according to the 2010 McDonald criteria with or without DMT in patients with insufficient VD levels (<30 ng/mL). Patients received VD supplement (calcifediol 0.266 mg) at a dosage of 1 ampoule orally per month. The exclusion criteria included relapse or corticosteroid treatment in the previous 30 days and contraindication to VD supplementation. In Figure 1, a healthy control group supplemented with vitamin D (VD) was not included. This decision was based on our group’s previous data, where we observed initial differences in gene expression for SMAD7 between healthy donors and individuals with multiple sclerosis (MS) [10]. Therefore, including such differences could potentially obscure any effects of vitamin D on gene expression in healthy donors. Relapses were defined as new symptoms or worsening of pre-existing neurological symptoms lasting more than 24 h after a period of 30 days of improvement or stability in the absence of fever or infection. Patients signed a written informed consent form. This study followed the recommendations of the Declaration of Helsinki and was approved by the ethics committee of Hospital General Universitario Gregorio Marañón (234/16).
4.2. Isolation and Culture of CD4+ T Cells
Blood samples (20 mL) were drawn in EDTA anticoagulant tubes at baseline and 1 month and 6 months after initiation of VD supplementation. Samples were processed immediately after collection under sterile conditions. Peripheral blood mononuclear cells were isolated by Ficoll gradient as described in [56]. CD4+ T-lymphocyte subtypes were negatively selected using the DynaBeads® UntouchedTM Human CD4 T Cells kit (Invitrogen, Waltham, MA, USA). Cells were counted, homogenized in Ribozol (Amresco, Solon, OH, USA), and stored at −80 °C in pellet form until RNA extraction.
4.3. RNA Isolation and cDNA Extraction
RNA from CD4+ T lymphocytes was isolated using the Ribozol Plus RNA purification kit (Amresco) following the manufacturer’s instructions. The concentration of the RNA obtained was quantified using spectrophotometry in a Quawell Q5000 device (Quawell Technology, Sunnyvale, CA, USA), and its integrity was verified in a 2100 Bioanalyzer device (Agilent Technologies, Santa Clara, CA, USA) using the RNA 6000 kit (Agilent). All RNAs had an integrity number (RIN) ≥ 8 and were, therefore, used for semi-quantitative real-time PCR (qRT-PCR).
4.4. Quantitative Real-Time PCR (qRT–PCR)
Candidate genes representative of the different TGF-β pathways were selected. SMAD7 was selected as a regulatory gene for the canonical SMAD pathway, ERK1 as a representative gene for the non-SMAD pathway, ZMIZ1 as a regulatory gene for PIAS expression, and BMPs as members of the TGF-β superfamily. We selected BMP2, BMPRII, BMP4, and BMP5 for their increased expression in the MS lesions assessed in previous studies. Changes in selected genes were analyzed in 21 RRMS patients at baseline and one month and six months after the start of VD supplementation. The cDNAs were generated from 500 ng of RNA using the High Capacity cDNA Archive Kit (Invitrogen) in 20 μL of final volume at 37 °C for 2 h. The enzyme was inactivated at 85 °C for 15 min. Relative quantification of gene expression was performed using qRT-PCRs in triplicate with 2 μL of cDNA per well (1/10 dilution), 1 × SYBR Green PCR Master Mix (Roche Applied Science, Penzberg, Germany), and 0.04 μM of oligonucleotides specific for SMAD7 (F-ACCCGATGGATTTTCTCAA; R-AGGGGCCAGATAATTCGTTC), ERK1 (F-CCCTAGCCCAGACAGACATC; R-GCACAGTGTCCATTTTCTAACAGT), ZMIZ1 (F-TTAGAGGGTCAGGCCGGAGC; R-TCGGGAAGGAGATCCAGCGAA), BMP2 (F-TCCACCATGAAGAATCTTTG; R-TAATTCGGTGATGGAAACTG), BMPRII (F-CCCGCTCCTACCTCTCCT; R-CGCAGAACAACCGTGAGAG), BMP4 (F-CTGCAACCGTTCAGAGGTC; R-TGCTCGGGATGGCACTAC), BMP5 (F-ATGGCAGGACTGGATTATAG; R-AGAGTCTGAACTATAGCGTG), and GAPDH (F-AGCCACATCGCTCAGACAC; R-GCCCAATACGACCAAATCC). PCR reactions were performed on a StepOne Plus thermal cycler (Applied Biosystems, Foster City, CA, USA). The relative expression of the genes analyzed was quantified using the 2−∆∆Ct method with StepOnePlus v2.3 software (Applied Biosystems). The GAPDH gene was used to normalize expression.
4.5. Clinical-Radiological Disease Activity
Clinical-radiological disease activity was measured at baseline and one year after the start of supplementation using the Rio-Score, which combines relapse, EDSS, and magnetic resonance imaging (MRI) criteria. The relapse criterion scored one point if the patient had ≥1 relapse per year. The EDSS criterion scored one point if the patient had an increase of ≥1 point on the EDSS scale, maintained for at least 6 months and confirmed at 1 year of the study. The MRI criterion scored one point if the patient had >2 active lesions (with respect to a previous annual MRI), defined as new or T2-enhancing lesions, plus the number of gadolinium-enhancing T1 lesions. The Rio-Score value was between 0 and 3. An increase in the Rio-Score value at 1 year compared to baseline was considered a deterioration in the Rio-Score, whereas a decrease in the value at 1 year compared to baseline was considered an improvement in the Rio-Score. Alternatively, an increase in the EDSS score at 1 year compared to baseline was considered a deterioration in the EDSS, while a decrease in the score at 1 year compared to baseline was considered an improvement in the EDSS.
4.6. Statistical Analysis
For qRT-PCR, relative expression was analyzed using the 2−ΔΔCt method with StepOne Software v2.3 (Applied Biosystems). Relative quantification was measured using Expression Suite software v1.3 (Life Technologies, Carlsbad, CA, USA). GraphPad Prism (v.8, Irvine, CA, USA) software was used for expression graphing. ANOVA and a paired t test were performed to identify differentially expressed genes. The Pearson correlation was used to study the association between variables. A p value ≤ 0.05 was considered statistically significant. The clinical-radiological activity variables were analyzed using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp., Armonk, NY, USA).
5. Conclusions
VD indirectly regulates the in vivo expression of genes related to the TGF-β signaling pathway in RRMS patients. Increased expression of SMAD7 and ERK1 suggests that VD could affect both SMAD and non-SMAD signaling pathways, which are critical for the dual functions of TGF-β in the immune system and in MS. Knowledge of the mechanisms of action of VD may yield biomarkers of response. Our study could have been limited by the impact of DMT mechanisms of action on gene expression and the evaluation of other subtypes of peripheral blood mononuclear cells. Further studies in larger cohorts are needed to elucidate the mechanisms by which VD exerts this regulation.
Conceptualization, A.L.-R., J.M.G.-D. and L.A.L.-F.; methodology, A.L.-R. and L.A.L.-F.; formal analysis, A.L.-R., S.S.-M. and L.A.L.-F.; data curation, A.L.-R., J.M.G.-D., M.L.M.-G., H.G.-B., S.S.-M., J.P.C., A.M.-R., Y.H.-H., M.S.-S. and L.A.Á.-S.-W.; writing—original draft preparation, A.L.-R. and L.A.L.-F.; writing—review and editing, all. All authors have read and agreed to the published version of the manuscript.
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón (protocol code 234/16, 13 September 2016).
Informed consent was obtained from all subjects involved in the study.
Data available in
We are particularly grateful to the study patients for their participation.
The authors declare that they have no conflict of interest. The funders had no role in the design of the study, in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 1. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients at baseline, after one month of supplementation, and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation. * p < 0.05; ** p < 0.01. Relative quantification of expression is represented as the mean of relative individual expression value; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 2. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with and without natalizumab at baseline, after one month of supplementation, and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, natalizumab; Green, no natalizumab. ** p < 0.01. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 2. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with and without natalizumab at baseline, after one month of supplementation, and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, natalizumab; Green, no natalizumab. ** p < 0.01. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 3. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with improvement or no change in the Rio-Score versus worsening in the Rio-Score at baseline, after one month of supplementation, and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, improvement or no change in the Rio-Score; Green, worsening in the Rio-Score. * p < 0.05; ** p < 0.01. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 3. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with improvement or no change in the Rio-Score versus worsening in the Rio-Score at baseline, after one month of supplementation, and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, improvement or no change in the Rio-Score; Green, worsening in the Rio-Score. * p < 0.05; ** p < 0.01. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 4. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with or without relapses of the disease at baseline, after one month of supplementation and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, relapse; Green, no relapse. * p < 0.05. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 4. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with or without relapses of the disease at baseline, after one month of supplementation and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, relapse; Green, no relapse. * p < 0.05. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Enlarge this image.Figure 5. Relative expression of selected genes in relapsing-remitting multiple sclerosis patients with improvement in the EDSS versus worsening or no change in the EDSS at baseline, after one month of supplementation, and after six months of supplementation. (a) SMAD7; (b) ERK1; (c) ZMIZ1; (d) BMP2; (e) BMPRII; (f) BMP4; and (g) BMP5; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; Red, improvement in the EDSS; Green, worsening or no change in the EDSS. * p < 0.05. Relative quantification of expression is represented as the mean of relative individual expression values; the error bars indicate the standard error of the mean.
Patient characteristics.
| Characteristic | RRMS |
|---|---|
| Median age, years (IQR, min–max) | 39 (11.5, 20–56) |
| Sex | |
| Women n, (%) | 16 (76.2%) |
| Men n, (%) | 5 (23.8%) |
| Months from diagnosis to sample collection, Median (IQR, min–max) | 95 (115.3, 15–272) |
| Type of disease-modifying treatment (n) | |
| Baseline–end | |
| Interferon beta-1a im | 3–3 |
| Glatiramer acetate | 4–3 |
| Teriflunomide | 2–1 |
| Dimethyl fumarate | 3–3 |
| Natalizumab | 9–10 |
| Alemtuzumab | 0–1 |
| Serum vitamin D levels (ng/mL) Median, IQR (min–max) | |
| T0 | 24.4, 5.5 (10.1–29.5) |
| T1 | 33.8, 11.2 (13.1–80.4) |
| T6 | 35.8, 6.9 (17.0–48.0) |
| EDSS Median, IQR (min–max) Baseline–end | 1.0, 2.2 (0–6) |
| Rio-Score n, (%) Baseline–end | |
| 0 | 10 (47.6%)–15 (71.4%) |
| 1 | 7 (33.3%)–5 (23.8%) |
| 2 | 2 (14.3%)–1 (4.8%) |
| 3 | 1 (4.8%)–0 (0%) |
RRMS, relapsing-remitting multiple sclerosis; im, intramuscular; T0, baseline; T1, after one month of supplementation; T6, after six months of supplementation; EDSS, expanded disability status scale.
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Garg, N.; Smith, T.W. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav.; 2015; 5, e00362. [DOI: https://dx.doi.org/10.1002/brb3.362] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26445701]
2. Hemmer, B.; Kerschensteiner, M.; Korn, T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol.; 2015; 14, pp. 406-419. [DOI: https://dx.doi.org/10.1016/S1474-4422(14)70305-9] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25792099]
3. Ascherio, A.; Munger, K.L.; White, R.; Köchert, K.; Simon, K.C.; Polman, C.H.; Freedman, M.S.; Hartung, H.-P.; Miller, D.H.; Montalbán, X. et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol.; 2014; 71, pp. 306-314. [DOI: https://dx.doi.org/10.1001/jamaneurol.2013.5993] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24445558]
4. Lucas, R.M.; Gorman, S.; Geldenhuys, S.; Hart, P.H. Vitamin D and immunity. F1000Prime Rep.; 2014; 6, 118. [DOI: https://dx.doi.org/10.12703/P6-118] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25580272]
5. Smolders, J.; Thewissen, M.; Peelen, E.; Menheere, P.; Tervaert, J.W.C.; Damoiseaux, J.; Hupperts, R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE; 2009; 4, e6635. [DOI: https://dx.doi.org/10.1371/journal.pone.0006635]
6. Sotirchos, E.S.; Bhargava, P.; Eckstein, C.; Van Haren, K.; Baynes, M.; Ntranos, A.; Gocke, A.; Steinman, L.; Mowry, E.M.; Calabresi, P.A. Safety and immunologic effects of high-vs low-dose cholecalciferol in multiple sclerosis. Neurology; 2016; 86, pp. 382-390. [DOI: https://dx.doi.org/10.1212/WNL.0000000000002316]
7. Christakos, S.; Dhawan, P.; Verstuyf, A.; Verlinden, L.; Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol. Rev.; 2016; 96, pp. 365-408. [DOI: https://dx.doi.org/10.1152/physrev.00014.2015]
8. Heldin, C.H.; Moustakas, A. Role of Smads in TGFβ signaling. Cell Tissue Res.; 2012; 347, pp. 21-36. [DOI: https://dx.doi.org/10.1007/s00441-011-1190-x]
9. Meoli, E.M.; Oh, U.; Grant, C.W.; Jacobson, S. TGF-β signaling is altered in the peripheral blood of subjects with multiple sclerosis. J. Neuroimmunol.; 2011; 230, pp. 164-168. [DOI: https://dx.doi.org/10.1016/j.jneuroim.2010.10.028]
10. Abarca-Zabalía, J.; García, M.I.; Ros, A.L.; Marín-Jiménez, I.; Martínez-Ginés, M.L.; López-Cauce, B.; Martín-Barbero, M.L.; Salvador-Martín, S.; Sanjurjo-Saez, M.; García-Domínguez, J.M. et al. Differential expression of SMAD genes and S1PR1 on circulating cd4+ t cells in multiple sclerosis and crohn’s disease. Int. J. Mol. Sci.; 2020; 21, 676. [DOI: https://dx.doi.org/10.3390/ijms21020676]
11. Kamato, D.; Burch, M.L.; Piva, T.J.; Rezaei, H.B.; Rostam, M.A.; Xu, S.; Zheng, W.; Little, P.J.; Osman, N. Transforming growth factor-β signalling: Role and consequences of Smad linker region phosphorylation. Cell. Signal.; 2013; 25, pp. 2017-2024. [DOI: https://dx.doi.org/10.1016/j.cellsig.2013.06.001] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23770288]
12. Moustakas, A.; Heldin, C.-H. Non-Smad TGF-beta signals. J. Cell Sci.; 2005; 118, pp. 3573-3584. [DOI: https://dx.doi.org/10.1242/jcs.02554] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16105881]
13. Hasan, M.; Neumann, B.; Haupeltshofer, S.; Stahlke, S.; Claudio Fantini, M.; Angstwurm, K.; Bogdahn, U.; Kleiter, I. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation. Immunol. Cell Biol.; 2015; 93, pp. 662-672. [DOI: https://dx.doi.org/10.1038/icb.2015.21]
14. Li, X.; Thyssen, G.; Beliakoff, J.; Sun, Z. The Novel PIAS-like Protein hZimp10 Enhances Smad Transcriptional Activity. J. Biol. Chem.; 2006; 281, pp. 23748-23756. [DOI: https://dx.doi.org/10.1074/jbc.M508365200] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16777850]
15. Fewings, N.L.; Gatt, P.N.; McKay, F.C.; Parnell, G.P.; Schibeci, S.D.; Edwards, J.; Basuki, M.A.; Goldinger, A.; Fabis-Pedrini, M.J.; Kermode, A.G. et al. The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis. J. Autoimmun.; 2017; 78, pp. 57-69. [DOI: https://dx.doi.org/10.1016/j.jaut.2016.12.006]
16. Shirvani-Farsani, Z.; Behmanesh, M.; Mohammadi, S.M.; Moghadasi, A.N. Vitamin D levels in multiple sclerosis patients: Association with TGF-β2, TGF-βRI, and TGF-βRII expression. Life Sci.; 2015; 134, pp. 63-67. [DOI: https://dx.doi.org/10.1016/j.lfs.2015.05.017]
17. Eixarch, H.; Calvo-Barreiro, L.; Montalban, X.; Espejo, C. Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation. Brain. Behav. Immun.; 2018; 68, pp. 1-10. [DOI: https://dx.doi.org/10.1016/j.bbi.2017.02.019]
18. Sotiropoulos, M.G.; Chitnis, T. Opposing and potentially antagonistic effects of BMP and TGF-β in multiple sclerosis: The “Yin and Yang” of neuro-immune Signaling. J. Neuroimmunol.; 2020; 347, 577358. [DOI: https://dx.doi.org/10.1016/j.jneuroim.2020.577358] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32795734]
19. Mausner-Fainberg, K.; Benhamou, M.; Golan, M.; Kimelman, N.B.; Danon, U.; Marom, E.; Karni, A. Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders. Neurotherapeutics; 2021; 18, pp. 1798-1814. [DOI: https://dx.doi.org/10.1007/s13311-021-01068-9]
20. Voumvourakis, K.I.; Antonelou, R.C.; Kitsos, D.K.; Stamboulis, E.; Tsiodras, S. TGF-β/BMPs: Crucial crossroad in neural autoimmune disorders. Neurochem. Int.; 2011; 59, pp. 542-550. [DOI: https://dx.doi.org/10.1016/j.neuint.2011.06.004]
21. Mausner-Fainberg, K.; Urshansky, N.; Regev, K.; Auriel, E.; Karni, A. Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol.; 2013; 264, pp. 91-99. [DOI: https://dx.doi.org/10.1016/j.jneuroim.2013.09.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24080309]
22. Costa, C.; Eixarch, H.; Martínez-Sáez, E.; Calvo-Barreiro, L.; Calucho, M.; Castro, Z.; Ortega-Aznar, A.; Ramón y Cajal, S.; Montalban, X.; Espejo, C. Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions. Am. J. Pathol.; 2019; 189, pp. 665-676. [DOI: https://dx.doi.org/10.1016/j.ajpath.2018.11.007] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30553833]
23. Sundström, P.; Salzer, J. Vitamin D and multiple sclerosis-from epidemiology to prevention. Acta Neurol. Scand.; 2015; 132, pp. 56-61. [DOI: https://dx.doi.org/10.1111/ane.12432] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26046560]
24. Deluca, H.F.; Cantorna, M.T. Vitamin D: Its role and uses in immunology 1. FASEB J.; 2001; 15, pp. 2579-2585. [DOI: https://dx.doi.org/10.1096/fj.01-0433rev] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11726533]
25. Lysandropoulos, A.P.; Jaquiéry, E.; Jilek, S.; Pantaleo, G.; Schluep, M.; Du Pasquier, R.A. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J. Neuroimmunol.; 2011; 233, pp. 240-244. [DOI: https://dx.doi.org/10.1016/j.jneuroim.2010.11.008]
26. Kebir, H.; Kreymborg, K.; Ifergan, I.; Dodelet-Devillers, A.; Cayrol, R.; Bernard, M.; Giuliani, F.; Arbour, N.; Becher, B.; Prat, A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med.; 2007; 13, pp. 1173-1175. [DOI: https://dx.doi.org/10.1038/nm1651]
27. Mangan, P.R.; Harrington, L.E.; O’Quinn, D.B.; Helms, W.S.; Bullard, D.C.; Elson, C.O.; Hatton, R.D.; Wahl, S.M.; Schoeb, T.R.; Weaver, C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature; 2006; 441, pp. 231-234. [DOI: https://dx.doi.org/10.1038/nature04754]
28. Mirshafiey, A.; Mohsenzadegan, M. TGF-β as a promising option in the treatment of multiple sclerosis. Neuropharmacology; 2009; 56, pp. 929-936. [DOI: https://dx.doi.org/10.1016/j.neuropharm.2009.02.007]
29. Kleiter, I.; Song, J.; Lukas, D.; Hasan, M.; Neumann, B.; Croxford, A.L.; Pedré, X.; Hövelmeyer, N.; Yogev, N.; Mildner, A. et al. Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain; 2010; 133, pp. 1067-1081. [DOI: https://dx.doi.org/10.1093/brain/awq039]
30. Zhang, Y.E. Non-Smad signaling pathways of the TGF-β family. Cold Spring Harb. Perspect. Biol.; 2017; 9, a022129. [DOI: https://dx.doi.org/10.1101/cshperspect.a022129]
31. Budi, E.H.; Duan, D.; Derynck, R. Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility. Trends Cell Biol.; 2017; 27, pp. 658-672. [DOI: https://dx.doi.org/10.1016/j.tcb.2017.04.005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28552280]
32. Akhurst, R.J.; Hata, A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov.; 2012; 11, pp. 790-811. [DOI: https://dx.doi.org/10.1038/nrd3810] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23000686]
33. Nanduri, R.; Mahajan, S.; Bhagyaraj, E.; Sethi, K.; Kalra, R.; Chandra, V.; Gupta, P. The active form of vitamin D transcriptionally represses Smad7 signaling and activates extracellular signal-regulated kinase (ERK) to inhibit the differentiation of a inflammatory T helper cell subset and suppress experimental autoimmune encephalomyelitis. J. Biol. Chem.; 2015; 290, pp. 12222-12236. [DOI: https://dx.doi.org/10.1074/jbc.M114.621839] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25809484]
34. Naghavi Gargari, B.; Behmanesh, M.; Shirvani Farsani, Z.; Pahlevan Kakhki, M.; Azimi, A.R. Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients. Int. Immunopharmacol.; 2015; 28, pp. 414-419. [DOI: https://dx.doi.org/10.1016/j.intimp.2015.06.033]
35. Farsani, Z.S.; Behmanesh, M.; Sahraian, M.A. Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple. J. Neurol. Sci.; 2015; 350, pp. 18-23. [DOI: https://dx.doi.org/10.1016/j.jns.2015.01.030]
36. Kim, D.; Witt, E.E.; Schubert, S.; Sotirchos, E.; Bhargava, P.; Mowry, E.M.; Sachs, K.; Bilen, B.; Steinman, L.; Awani, A. et al. Peripheral T-Cells, B-Cells, and Monocytes from Multiple Sclerosis Patients Supplemented with High-Dose Vitamin D Show Distinct Changes in Gene Expression Profiles. Nutrients; 2022; 14, 4737. [DOI: https://dx.doi.org/10.3390/nu14224737]
37. Waisman, A.; Hauptmann, J.; Regen, T. The role of IL-17 in CNS diseases. Acta Neuropathol.; 2015; 129, pp. 625-637. [DOI: https://dx.doi.org/10.1007/s00401-015-1402-7]
38. Khoy, K.; Mariotte, D.; Defer, G.; Petit, G.; Toutirais, O.; Le Mauff, B. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front. Immunol.; 2020; 11, 549842. [DOI: https://dx.doi.org/10.3389/fimmu.2020.549842]
39. Clerico, M.; Artusi, C.A.; Liberto, A.D.; Rolla, S.; Bardina, V.; Barbero, P.; De Mercanti, S.F.; Durelli, L. Natalizumab in Multiple Sclerosis: Long-Term Management. Int. J. Mol. Sci.; 2017; 18, 940. [DOI: https://dx.doi.org/10.3390/ijms18050940]
40. Ara, J.; See, J.; Mamontov, P.; Hahn, A.; Bannerman, P.; Pleasure, D.; Grinspan, J.B. Bone morphogenetic proteins 4, 6, and 7 are up-regulated in mouse spinal cord during experimental autoimmune encephalomyelitis. J. Neurosci. Res.; 2008; 86, pp. 125-135. [DOI: https://dx.doi.org/10.1002/jnr.21462]
41. Río, J.; Nos, C.; Tintoré, M.; Téllez, N.; Galán, I.; Pelayo, R.; Comabella, M.; Montalban, X. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol.; 2006; 59, pp. 344-352. [DOI: https://dx.doi.org/10.1002/ana.20740] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16437558]
42. Río, J.; Castilló, J.; Rovira, A.; Tintoré, M.; Sastre-Garriga, J.; Horga, A.; Nos, C.; Comabella, M.; Aymerich, X.; Montalbán, X. Measures in the first year of therapy predict the response to interferon beta in MS. Mult. Scler.; 2009; 15, pp. 848-853. [DOI: https://dx.doi.org/10.1177/1352458509104591] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19542263]
43. Sormani, M.P.; Rio, J.; Tintorè, M.; Signori, a.; Li, D.; Cornelisse, P.; Stubinski, B.; Stromillo, M.L.; Montalban, X.; De Stefano, N. Scoring treatment response in patients with relapsing multiple sclerosis. Mult. Scler. J.; 2013; 19, pp. 605-612. [DOI: https://dx.doi.org/10.1177/1352458512460605] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23012253]
44. Penn, M.; Mausner-Fainberg, K.; Golan, M.; Karni, A. High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol.; 2017; 310, pp. 120-128. [DOI: https://dx.doi.org/10.1016/j.jneuroim.2017.07.008] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28778435]
45. Grinspan, J.B.; Edell, E.; Carpio, D.F.; Beesley, J.S.; Lavy, L.; Pleasure, D.; Golden, J.A. Stage-specific effects of bone morphogenetic proteins on the oligodendrocyte lineage. J. Neurobiol.; 2000; 43, pp. 1-17. [DOI: https://dx.doi.org/10.1002/(SICI)1097-4695(200004)43:1<1::AID-NEU1>3.0.CO;2-0]
46. Mabie, P.C.; Mehler, M.F.; Marmur, R.; Papavasiliou, A.; Song, Q.; Kessler, J.A. Bone morphogenetic proteins induce astroglial differentiation of oligodendroglial-astroglial progenitor cells. J. Neurosci.; 1997; 17, pp. 4112-4120. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.17-11-04112.1997]
47. Colak, D.; Mori, T.; Brill, M.S.; Pfeifer, A.; Falk, S.; Deng, C.; Monteiro, R.; Mummery, C.; Sommer, L.; Götz, M. Adult neurogenesis requires Smad4-mediated bone morphogenic protein signaling in stem cells. J. Neurosci.; 2008; 28, pp. 434-446. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.4374-07.2008]
48. Coskun, V.; Venkatraman, G.; Yang, H.; Rao, M.S.; Luskin, M.B. Retroviral manipulation of the expression of bone morphogenetic protein receptor Ia by SVZa progenitor cells leads to changes in their p19(INK4d) expression but not in their neuronal commitment. Int. J. Dev. Neurosci. Off. J. Int. Soc. Dev. Neurosci.; 2001; 19, pp. 219-227. [DOI: https://dx.doi.org/10.1016/S0736-5748(00)00092-7]
49. Lu, L.; Ma, J.; Wang, X.; Wang, J.; Zhang, F.; Yu, J.; He, G.; Xu, B.; Brand, D.D.; Horwitz, D.A. et al. Synergistic effect of TGFbeta superfamily members on the induction of FoxP3+ regulatory cells. Eur. J. Immunol.; 2010; 40, pp. 142-152. [DOI: https://dx.doi.org/10.1002/eji.200939618]
50. Hupperts, R.; Smolders, J.; Vieth, R.; Holmøy, T.; Marhardt, K.; Schluep, M.; Killestein, J.; Barkhof, F.; Beelke, M.; Grimaldi, L.M.E. Randomized trial of daily high-dose Vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology; 2019; 93, pp. E1906-E1916. [DOI: https://dx.doi.org/10.1212/WNL.0000000000008445]
51. Smolders, J.; Hupperts, R.; Barkhof, F.; Grimaldi, L.M.E.; Holmoy, T.; Killestein, J.; Rieckmann, P.; Schluep, M.; Vieth, R.; Hostalek, U. et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J. Neurol. Sci.; 2011; 311, pp. 44-49. [DOI: https://dx.doi.org/10.1016/j.jns.2011.04.013] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21620416]
52. Camu, W.; Lehert, P.; Pierrot-Deseilligny, C.; Hautecoeur, P.; Besserve, A.; Deleglise, A.S.J.; Payet, M.; Thouvenot, E.; Souberbielle, J.C. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol. Neuroimmunol. NeuroInflamm.; 2019; 6, e597. [DOI: https://dx.doi.org/10.1212/NXI.0000000000000597]
53. Smolders, J.; Torkildsen, Ø.; Camu, W.; Holmøy, T. An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs; 2019; 33, pp. 1187-1199. [DOI: https://dx.doi.org/10.1007/s40263-019-00674-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31686407]
54. Sîrbe, C.; Rednic, S.; Grama, A.; Pop, T.L. An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases. Int. J. Mol. Sci.; 2022; 23, 9784. [DOI: https://dx.doi.org/10.3390/ijms23179784] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36077185]
55. Munger, K.L.; Köchert, K.; Simon, K.C.; Kappos, L.; Polman, C.H.; Freedman, M.S.; Hartung, H.P.; Miller, D.H.; Montalbán, X.; Edan, G. et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann. Clin. Transl. Neurol.; 2014; 1, pp. 605-617. [DOI: https://dx.doi.org/10.1002/acn3.91]
56. De Andres, C.; García, M.I.; Goicoechea, H.; Martínez-Ginés, M.L.; García-Domínguez, J.M.; Martín, M.L.; Romero-Delgado, F.; Benguría, A.; Sanjurjo, M.; López-Fernández, L.A. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: Potential biomarkers. Pharmacogenomics J.; 2018; 18, pp. 98-105. [DOI: https://dx.doi.org/10.1038/tpj.2016.71]
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; López-Fernández, Luis A 2
1 Servicio de Neurología, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain;
2 Servicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain;
3 Servicio de Medicina Interna, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain;